Boston Scientific gets CE mark for expanded CRM longevity

Boston Scientific got European approval to extend the labeled longevity of devices like Energen--courtesy of Boston Scientific

Like most devicemakers, Boston Scientific ($BSX) is struggling with a decrease in demand for cardiac rhythm management products, but a European regulatory approval might give it a leg up on competitors. The company got a CE mark to increase its longevity projections for its heart devices, which are now labeled to last up to 10 years.

That's twice the projected shelf life of some of its competitors, Boston Sci says, and the new labels could help the company snag more European market share for devices such as Incepta, Energen and Puctua. The company offers warranties of up to 10 years on the devices, and Senior Vice President Michael Onuscheck the expanded labeling provides further assurance to doctors and patients.

"Boston Scientific ICDs and CRT-Ds benefit from our proprietary advanced battery technology," Onuscheck said in a statement. "The new battery was first introduced in the Cognis and Teligen devices in 2008 and has now been incorporated into our newest devices."

With expanded longevity projections, Boston Sci can better make the case for its products' value to payers and physicians, the company said. And, considering the company's sales numbers, it can't hurt. In the last quarter, Boston Sci's cardiac rhythm management revenues dropped 8% to $462 million, and the company reported an $809 million goodwill charge related to the shrinking CRM market.

- read Boston Sci's release

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.